---
layout: post
title: "哈三联：注射用奥美拉唑钠通过一致性评价"
date: 2022-01-05 17:14:05 +0800
categories: zhengquanshibao
tags: 证券时报新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/0.002900" data-code="002900|0|2" data-code2="002900|0|6|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=0.002900&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 002900_0" data-code="K 002900|0|2" data-code2="K 002900|0|6|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>哈三联(002900)1月5日晚间公告，公司于近日收到国家药监局核准签发的药品补充申请批准通知书，公司产品注射用奥美拉唑钠通过了仿制药质量和疗效一致性评价。注射用奥美拉唑钠主要适用于消化性溃疡出血、吻合口溃疡出血等。<br /></p><p class="em_media">（文章来源：证券时报）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202201052237304948>

[返回证券时报新闻](//finews.withounder.com/category/zhengquanshibao.html)｜[返回首页](//finews.withounder.com/)